2024
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.Peer-Reviewed Original ResearchEmerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptions
2023
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune-related adverse eventsPre-existing autoimmune diseaseAutoimmune diseasesCheckpoint inhibitorsFlare-upBenefit of immune checkpoint inhibitorsAutoimmune disease flare-upManagement of flare-upsPre-existing autoimmune disordersImmune checkpoint inhibitor treatmentCancer CenterDisease flare-upContext of autoimmune diseasesAutoimmune disease progressionAutoimmune disease treatmentAutoimmune disordersAdverse eventsTreatment modificationOrgan damageComprehensive cancer centerDisease progressionPatientsCancerUS cancer centers
2021
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis
Kim S, Pundole X, Dadu R, Lambotte O, Ramos-Casals M, Suarez-Almazor M. Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy 2021, 13: 465-475. PMID: 33641345, PMCID: PMC7983044, DOI: 10.2217/imt-2020-0272.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsHistory of sarcoidosisPre-existing sarcoidosisCancer patientsCheckpoint inhibitorsRemote historyDose of atezolizumabEvaluate adverse eventsFrequency of flaresICI initiationHilar lymphadenopathySymptomatic exacerbationAdverse eventsSarcoidosisSubcutaneous nodulesPatientsFluctuating courseAtezolizumabCancerInhibitorsUveitisPrednisoneLymphadenopathyExacerbationDoseCancer Immunology and the Evolution of Immunotherapy
Nurieva R, Divenko M, Kim S. Cancer Immunology and the Evolution of Immunotherapy. 2021, 3-29. DOI: 10.1007/978-3-030-56824-5_1.Peer-Reviewed Original ResearchDevelopment of cancer immunotherapeuticsHost anti-tumor immunityCancer immunotherapy modalitiesEvolution of immunotherapyAnti-tumor immunityHost immune cellsImmunotherapy modalitiesCancer immunotherapyCancer immunotherapeuticsCancer immunologyImmune cellsTumor cellsCellular mechanisms of interactionCancer cellsCancerCellular mechanismsImmunotherapyCellsImmunotherapeuticsTumorImmunityImmunologyFDAModalitiesTrials